drugset / Trial / NCT06110663
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
HS-10241, an oral and highly selective MET-TKI, may contribute to overcoming common acquired MET-based resistance mechanisms following prior EGFR-TKI monotherapy. This study is conducted to evaluate the efficacy and safety of HS-10241 combined with Almonertinib versus platinum-based chemotherapy in NSCLC with MET amplification after failure of EGFR-TKI treatment.
Timeline
- Start
- 2023-12-30
- Primary completion
- 2024-12-30
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | 110 mg | Oral |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Subject | HS-10241 | Small molecule | 300 mg | Oral |
| Comparator | Pemetrexed | Small molecule | — | — |